EUVIMEDEUVIMED entdecken
Crossref

Claudin‐4 immunocytochemistry is specific and sensitive for the diagnosis of malignant carcinomatous effusions: Results from a pilot study

Vanlal Hruaii, Balamurugan Thirunavukkarasu iD, Vindhya Prabha, Sandeep Mathur, Venkateswaran K Iyer, Aruna Nambirajan, Deepali Jain iD

Diagnostic Cytopathology · 2024

DOI: 10.1002/dc.25238 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diagnostic Cytopathology, 2024. Verfasst von Vanlal Hruaii und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, All India Institute of Medical Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Carcinoma, Adenocarcinoma, Mesothelioma, Pleural Effusion, Malignant. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Claudin‐4, a tight junction associated protein expressed in epithelial cells, is purported as a highly specific and sensitive marker for epithelial malignancies. Our aim was to assess the sensitivity, specificity and real‐time utility of claudin‐4 immunocytochemistry (ICC) in the diagnostic work‐up of suspected malignant effusions.

Methods

Claudin‐4 (3E2C1 clone) ICC was performed prospectively in effusion cell blocks where other ICC markers were being performed as part of reporting over 3 months. Based on claudin‐4 staining in unequivocal malignant and reactive effusions, the sensitivity and specificity was calculated. In cases signed out as inconclusive encompassing atypia of undetermined significance (AUS) and suspicious for malignancy (SFM) and negative for malignancy, change in diagnostic category based on addition of claudin‐4 ICC was assessed.

Results

Study included 107 effusions. Claudin‐4 stained 100% of metastatic adenocarcinomas including those with primaries in lung, breast, ovary, female genital tract, gastrointestinal tract and pancreatic‐biliary tract, and was negative in all reactive mesothelial and mesothelioma effusions with sensitivity of 100% (48/48) and specificity of 95% (20/21) for adenocarcinoma. Claudin‐4 upgraded the diagnostic category to positive in 70% (16/23) of SFM, 20% (1/5) of AUS, and in 50% (5/10) of negative effusions. Among cases with confirmed serosal involvement status on follow‐up, claudin‐4 showed sensitivity, specificity, positive predictive value and negative predictive values of 85% (11/13), 100% (3/3), 100% (10/10) and 75% (3/4), respectively, for metastatic adenocarcinoma.

Conclusion

Claudin‐4 as a single marker is sensitive and specific for adenocarcinoma and is a valuable addition to the ICC armamentarium.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarcinomaAdenocarcinomaMesotheliomaPleural Effusion, MalignantHumansFemaleClaudin-4Pilot ProjectsImmunohistochemistryBiomarkers, TumorDiagnosis, Differential

Stichwörter der Autor:innen

carcinomacell blockclaudin-4effusionimmunochemistrymesothelioma

Substanzen

Claudin-4Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.

ORCID-Profile: Balamurugan Thirunavukkarasu, Deepali Jain

Zitieren

APA

Hruaii, V., Thirunavukkarasu, B., Prabha, V., Mathur, S., Iyer, V. K., Nambirajan, A., & Jain, D. (2024). Claudin‐4 immunocytochemistry is specific and sensitive for the diagnosis of malignant carcinomatous effusions: Results from a pilot study. Diagnostic Cytopathology. https://doi.org/10.1002/dc.25238

Vancouver

Hruaii V, Thirunavukkarasu B, Prabha V, Mathur S, Iyer VK, Nambirajan A, et al. Claudin‐4 immunocytochemistry is specific and sensitive for the diagnosis of malignant carcinomatous effusions: Results from a pilot study. Diagnostic Cytopathology. 2024. doi:10.1002/dc.25238

BibTeX
@article{Hruaii2024,
  author = {Hruaii, Vanlal and Thirunavukkarasu, Balamurugan and Prabha, Vindhya and Mathur, Sandeep and Iyer, Venkateswaran K and Nambirajan, Aruna and Jain, Deepali},
  title = {Claudin‐4 immunocytochemistry is specific and sensitive for the diagnosis of malignant carcinomatous effusions: Results from a pilot study},
  journal = {Diagnostic Cytopathology},
  year = {2024},
  doi = {10.1002/dc.25238}
}
Kostenlos starten →